Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development Service Platform
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon Support
IND 100 Publications
Nov 08,2019
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study, DMPK study and the safety evaluation. Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies.
See More
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Oct 30,2019
Medicilon assists pharmaceutical companies to successfully pass the consistency evaluation
Recently, Medicilon's CMC preparations have developed another success. Amlodipine besylate tablets, a cardiovascular drug 289 base drug project developed for customers for lowering blood pressure, has been obtained by the National Medical Products Administration (NMPA). This is one of the consistency evaluation drugs approved by Medicilon and its customers. The project lasted for nearly 3Read more
See More
Medicilon assists pharmaceutical companies to successfully pass the consistency evaluation
Oct 29,2019
Insulin Technology Achieves a New Breakthrough, Medicilon Helps to Make a New Leap Forward!
Medicilon has currently completed the pharmacokinetic study of common insulin and oral insulin compound preparations of a company in Jiangsu, administered the test product subcutaneously and orally, and measured the blood glucose level of animals with a Roche blood glucose meter;
See More
Insulin Technology Achieves a New Breakthrough, Medicilon Helps to Make a New Leap Forward!
Jun 07,2019
Medicilon helps ImmuneOnco Biopharma's target CD47 fusion protein drug to obtain NMPA clinical trial license
Recently, ImmuneOnco Biopharma, a partner of Shanghai Medicilon Inc., announced that its newly developed immune checkpoint inhibitor has been approved by the National Medical Products Administration (NMPA), which marks the beginning of a new phase of research on the first CD47 fusion protein drug in China. It is reported that ImmuneOnco Biopharma submitted the INDRead more
See More
Medicilon helps ImmuneOnco Biopharma's target CD47 fusion protein drug to obtain NMPA clinical trial license
Jul 02,2018
Huizhou Jizhong Biological Technology's Biological New Drug Obtained FDA Clinical Approval!
Recently, Huizhou Jizhong Biological Technology's innovative drug local anesthetic injection - a new long-acting postoperative analgesic successfully obtained FDA (US Food and Drug Administration) new drug clinical trial approval!
See More
Huizhou Jizhong Biological Technology's Biological New Drug Obtained FDA Clinical Approval!
May 15,2018
Medicilon Assist: Haihe Biopharma and 3D Medicines Start Cooperation on New Anti-tumor Drugs
Haihe Biopharma and 3D Medicines announced on April 28 that the two parties have reached a strategic cooperation on the FGFR inhibitor (code-named "HH185") project of Haihe Biopharma.
See More
Medicilon Assist: Haihe Biopharma and 3D Medicines Start Cooperation on New Anti-tumor Drugs
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->